Abstract：
Among consecutive patients with multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia we found those treated with ceftazidime-avibactam were more likely to develop resistance (defined as ≥4-fold increased MIC) than those treated with ceftolozane-tazobactam (40% vs. 10%; P=0.002). Ceftazidime-avibactam resistance was associated with new mutations in ampC and efflux regulatory pathways.
摘要：
在连续的多药耐药铜绿假单胞菌菌血症或肺炎患者中，我们发现使用头孢他啶-阿维巴坦治疗的患者比使用头孢他啶-他唑巴坦治疗的患者更容易产生耐药性（定义为MIC增加≥4倍）（40％vs.10%；P=0.002）。头孢他啶-阿维巴坦耐药性与ampC和外排调节途径的新突变有关。
